BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23982740)

  • 1. The evolving landscape in the therapy of acute myeloid leukemia.
    Peloquin GL; Chen YB; Fathi AT
    Protein Cell; 2013 Oct; 4(10):735-46. PubMed ID: 23982740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.
    Pierceall WE; Lena RJ; Medeiros BC; Blake N; Doykan C; Elashoff M; Cardone MH; Walter RB
    Leuk Res; 2014 May; 38(5):564-8. PubMed ID: 24636337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
    Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
    Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
    O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
    Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab ozogamicin for acute myeloid leukemia.
    Appelbaum FR; Bernstein ID
    Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
    Bazinet A; Assouline S
    Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
    [No Abstract]   [Full Text] [Related]  

  • 12. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
    Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
    Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic strategies for high-risk acute myeloid leukemia.
    Menghrajani K; Tallman MS
    Curr Opin Hematol; 2018 Mar; 25(2):90-94. PubMed ID: 29283906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why is it so difficult to use gemtuzumab ozogamicin?
    Sylvie Castaigne
    Blood; 2013 Jun; 121(24):4813-4. PubMed ID: 23766456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
    Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
    Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
    Walter RB; Medeiros BC; Powell BL; Schiffer CA; Appelbaum FR; Estey EH
    Haematologica; 2012 May; 97(5):739-42. PubMed ID: 22133771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S
    Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug.
    Rowe JM; Löwenberg B
    Blood; 2013 Jun; 121(24):4838-41. PubMed ID: 23591788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.